Gemtuzumab ozogamicin (Mylotarg) in children with refractory or relapsed acute myeloid leukemia

Onkologie
D ReinhardtC M Zwaan

Abstract

Gemtuzumab ozogamicin (GO) is an immunoconjugate consisting of the CD33 antibody and calicheamicin, a potent cytotoxic agent. Developed for targeted treatment of CD33-positive AML, studies in adults showed its efficacy in relapsed and refractory AML. We report 12 children with multiple relapsed or refractory AML receiving GO as compassionate use. 11 children had initially been treated according to the AML-BFM 93 or 98 protocol, 1 girl received relapse treatment (liposomal daunorubicin/FLAG) due to secondary AML. After relapse, 10 children received an intensive relapse therapy (AML-BFM 97 or international AML-Relapse Study 2001/01). 2 of them had been transplanted in first or second CR before GO therapy. 5 of 12 children responded to treatment with blast reduction to below 5%, but no child achieved CR after GO. Time until reoccurrence of blasts in almost all children with GO response was 3-8 months. In 5 children stem cell transplantation (SCT) was performed after GO therapy. 4 of them suffered from further progression of AML, 1 boy is in second remission with a follow-up of 8 months. 2 children had severe side effects. An anaphylactic reaction with severe hypotension was managed by catecholamine support and intensive care. In 1...Continue Reading

Citations

Sep 5, 2008·Indian Journal of Pediatrics·Manasi Shah, Bharat Agarwal
May 28, 2013·International Journal of Hematology·Akihiro Takeshita
Feb 28, 2008·Current Opinion in Hematology·Sergio Amadori, Roberto Stasi
Oct 26, 2013·Paediatric Drugs·Jennifer DavilaThomas Renaud
Mar 21, 2008·Expert Opinion on Biological Therapy·Roberto Stasi
Oct 19, 2007·Cancer Treatment Reviews·Roberto StasiSergio Amadori
Sep 2, 2008·British Journal of Haematology·Benoit BrethonAndré Baruchel
Sep 26, 2006·Best Practice & Research. Clinical Haematology·Sergio Amadori, Roberto Stasi
Aug 11, 2012·Blood·Ursula CreutzigUNKNOWN AML Committee of the International BFM Study Group
Mar 29, 2014·Frontiers in Oncology·Sarah K TasianRichard Aplenc
Apr 11, 2009·Trends in Pharmacological Sciences·Mary K O'Reilly, James C Paulson
Dec 15, 2017·Journal of Pediatric Hematology/oncology·Anthony Pak-Yin LiuShau-Yin Ha
Dec 6, 2019·Frontiers in Pediatrics·Annalisa LonettiRiccardo Masetti

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Anaphylaxis

Anaphylaxis is a serious allergic reaction that is rapid in onset and may cause death.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.